*2.1. Materials*

Fenofibrate (FEN) (≥99%, powder) was purchased from Sigma-Aldrich (Castle Hill, Australia). Commercially available standard APO-fenofibrate tablets (Apotex, Macquarie Park, Australia) were purchased from local suppliers and crushed into a powder before use. The lipids, Capmul PG8, Captex 300 and Capmul MCM, were sourced from Abitec (Columbus, OH, USA). Fumed hydrophilic silica nanoparticles (Aerosil 300 Pharma), with a surface area of 300 <sup>±</sup> 30 m<sup>2</sup> /g were donated by Evonik (Melbourne, Australia). Mesoporous silica microparticles (Parteck SLC 500), with a particle size of 9–11 µm and pore size of 6 nm, and sodium lauryl sulfate (SLS) (used to prepare dissolution medium) were donated and purchased from Merck (Melbourne, Australia), respectively. Fasted state simulated intestinal fluid/fed state simulated intestinal fluid/fasted state simulated gastric fluid (FaSSIF/FeSSIF/FaSSGF) biorelevant powder, to prepare biorelevant media for gastrointestinal lipolysis, was obtained from Biorelevant (Biorelevant.com, London, UK). Porcine pancreatin extract was supplied by MP Biomedicals (Seven Hills, Australia). 4-bromophenylboronic acid (4-BBA) and lipase from *Candida antarctica* were purchased from Sigma-Aldrich (Castle Hill, Australia). HPLC-grade methanol was purchased from local suppliers. High purity Milli Q water (Merck Millipore, Bayswater, Australia) was used throughout the study.
